Results of Therapeutic Trials Using Anti-Idiotype Antibodies
| Therapy . | Patients Treated . | PR . | CR . | CR Durations (years) . |
|---|---|---|---|---|
| Anti-Id | 18 | 8 | 4 | 1.5, 4+, 7,-150 9.5+ |
| Anti-Id + IFN | 12 | 7 | 2 | 9.5+, 10+ |
| Anti-Id + Chl | 13 | 8 | 1 | 2.5 |
| Anti-Id + IL-2 | 9 | 2 | 1 | 4.5 |
| Totals | 52 | 25 | 8 |
| Therapy . | Patients Treated . | PR . | CR . | CR Durations (years) . |
|---|---|---|---|---|
| Anti-Id | 18 | 8 | 4 | 1.5, 4+, 7,-150 9.5+ |
| Anti-Id + IFN | 12 | 7 | 2 | 9.5+, 10+ |
| Anti-Id + Chl | 13 | 8 | 1 | 2.5 |
| Anti-Id + IL-2 | 9 | 2 | 1 | 4.5 |
| Totals | 52 | 25 | 8 |
Antibodies were given either alone or in combination with other agents: IFN, alpha interferon; Chl, chlorambucil; IL-2, interleukin-2.
Abbreviations: PR, partial remission; CR, complete remission.
Patient 1 received local XRT after a local relapse at 7 years and subsequently has been in continuous and ongoing remission for an additional 9 years.